GAM
AKBA icon

Gotham Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Gotham Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.8K Buy
27,172
+11,202
+70% +$15.4K ﹤0.01% 1742
2025
Q4 		$25.7K Buy
15,970
+1,471
+10% +$3.08K ﹤0.01% 1718
2025
Q3 		$39.6K Sell
14,499
-1,070
-7% -$3.56K ﹤0.01% 1669
2025
Q2 		$56.7K Buy
+15,569
New +$42.8K ﹤0.01% 1640
2021
Q3 		– Sell
-19,195
Closed -$73K – 1013
2021
Q2 		$73K Buy
+19,195
New +$64.6K ﹤0.01% 979

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Gotham Asset Management's AKBA Position: Q1 2026 in Review

Gotham Asset Management increased its Akebia Therapeutics (AKBA) stake by 70% in Q1 2026, buying an estimated $15.4K and bringing the position to 27,172 shares worth $37.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Gotham Asset Management first reported a position in AKBA in Q2 2021 and has held it in 5 quarters since. The position peaked at $73K in Q2 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Gotham Asset Management held 27,172 shares of Akebia Therapeutics worth $37.8K as of Q1 2026.
  • Gotham Asset Management bought 11,202 Akebia Therapeutics shares in Q1 2026, an estimated $15.4K.
  • Akebia Therapeutics made up ﹤0.01% of Gotham Asset Management's portfolio in Q1 2026, its #1742 holding.
  • Gotham Asset Management first reported a position in Akebia Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • Gotham Asset Management's Akebia Therapeutics position peaked at $73K in Q2 2021.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.